Faron Pharmaceuticals Oy (FRA:4FR) Institutional Ownership: 1.55% (As of Jul. 28, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:4FR Faron Pharmaceuticals Oy FRA:4FR
28 GF Score
Price €0.47
! 4 Warning Signs
View Full Analysis

What is Faron Pharmaceuticals Oy Institutional Ownership?

Faron Pharmaceuticals Oy FRA:4FR -2.61% 28 Institutional Ownership is 1.55% as of Jul. 28, 2026. GuruFocus rates FRA:4FR with a GF Score™ of 28/100. The stock has 4 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Faron Pharmaceuticals Oy's institutional ownership is 1.55%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Faron Pharmaceuticals Oy's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Faron Pharmaceuticals Oy's Float Percentage Of Total Shares Outstanding is 0.00%.

Faron Pharmaceuticals Oy Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Faron Pharmaceuticals Oy's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Faron Pharmaceuticals Oy Institutional Ownership Chart

Faron Pharmaceuticals Oy Historical Data

The historical data trend for Faron Pharmaceuticals Oy can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 5.27 5.12 4.91 4.85 4.66 2.97 2.43 1.58 1.58 1.55
FRA:4FR
28GF Score
Faron Pharmaceuticals Oy FRA:4FR
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Faron Pharmaceuticals Oy Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 1.55% mean?
Faron Pharmaceuticals Oy (FRA:4FR) has a Institutional Ownership of 1.55% as of Jul. 28, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Faron Pharmaceuticals Oy and its competitors.
Is Faron Pharmaceuticals Oy's Institutional Ownership too high?
Faron Pharmaceuticals Oy's current Institutional Ownership is 1.55%. Overall, Faron Pharmaceuticals Oy has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Faron Pharmaceuticals Oy's Institutional Ownership compare to VRTX and REGN?
Faron Pharmaceuticals Oy's Institutional Ownership of 1.55% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Faron Pharmaceuticals Oy and its competitors. Faron Pharmaceuticals Oy's current Institutional Ownership is 1.55%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Faron Pharmaceuticals Oy stock overvalued right now?
Faron Pharmaceuticals Oy (FRA:4FR) has a current Institutional Ownership of 1.55%. The current Institutional Ownership is 1.55%. Faron Pharmaceuticals Oy's overall GF Score™ is 28/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Faron Pharmaceuticals Oy (FRA:4FR), the current Institutional Ownership is 1.55% as of Jul. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Faron Pharmaceuticals Oy Business Description

Other Exchanges FARN:UKFARON:Finland
Address Joukahaisenkatu 6 B, Turku, FIN, 20520
Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company. The company has one operating and reportable segment. The Group has a pipeline based on the receptors involved in the regulation of immune response in oncology, organ damage, and bone marrow regeneration. Faron is a late clinical stage drug discovery and development Group. The company includes Bexmarilimab in its pipeline. Bexmarilimab is Faron's wholly owned, investigational immunotherapy designed to overcome resistance to existing treatments and improve clinical outcomes by targeting myeloid cell function in the microenvironment and igniting the immune system against cancer.
28GF Score

Get the complete analysis for FRA:4FR

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.47
Price